[Correspondence] Standardising MET amplification testing: limitations of the GCN ≥6 criterion

We read with great interest the phase 2 KUNPENG trial by Yi-Long Wu and colleagues.1 The reported objective response rate of 48·8% with vebreltinib in MET amplification-driven non-small-cell lung cancer is promising. However, the use of a gene copy number (GCN) of six or higher as the sole enrolment criterion obscures crucial biological heterogeneity within this population. This methodological choice…